Edwards Lifesciences Corporation EW is slated to report third-quarter 2020 results on Oct 21, after market close.
In the last reported quarter, the company posted an earnings surprise of 126.67%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
The third-quarter results are expected to reflect a mixed performance by the core Critical Care product group. The pandemic has continued to impact the procedural volumes in the segment, as elective procedures have been deferred. Global demand has been soft due to the pandemic-led business disruptions over the past few months.
However, management is optimistic about the robust customer adoption of the TruWave disposable pressure monitoring devices, despite the challenging pandemic-led market conditions. This is likely to be reflected in the third-quarter results. Robust demand for Edwards Lifesciences’ ICU products is also likely to have boosted the top line.
However, a decline in HemoSphere